1 Copenhagen Trial Unit, Cochranecenteret Rigshospitalet, Rigshospitalet, The Capital Region of Denmark2 unknown
Ursodeoxycholic acid is administered to patients with primary biliary cirrhosis, a chronic progressive inflammatory autoimmune-mediated liver disease with unknown aetiology. Despite its controversial effects, the U.S. Food and Drug Administration has approved its usage for primary biliary cirrhosis.
Cochrane Database of Systematic Reviews, 2012, Vol 12
Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't; Review